摘要
目的探讨环索奈德与孟鲁司特钠联合治疗对哮喘患者血清中白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-a)及痰液中白三烯(LTs)水平的影响。方法选择200例急性发作期哮喘患者,将其随机分为实验组(100例)和对照组(100例),对照组予以环索奈德治疗;实验组在对照组基础上,加用孟鲁司特钠治疗,服用2周。结果实验组有91%的患者达到临床控制,与对照组的78%相比较,差异有统计学意义(P<0.05),治疗4周、8周后患者血清中IL-6,TNF-α及痰液中LTs水平均较治疗前明显下降(P<0.05),且实验组比对照组下降更明显(P<0.05)。结论环索奈德联合孟鲁司特钠治疗哮喘的作用机制可能是通过下调血清中白介素-6(IL-6)、肿瘤坏死因子(TNF-α)及痰液中白三烯(LTs)的水平。
Objective To explore the level of IL-6, TNF-α and sputum LTs of ciclesonide combined montelukast in the treatment ofasthma.Methods 200patientswithacuteexacerbationofasthmawererandomlydividedintotheexperimentalgroup（100cases）and control group （ 100 cases ）.The control group were treated with ciclesonide ,and the experimental group were treatd with ciclesonide combinedmontelukast.Allpatientsweretreatedfortwoweeks.Results 91patientswithclinicalcontrolintheexperimentalgroup,and78 patients with clinical control in the control group （P〉0.05）,the IL-6, TNF-α and sputum LTs level were decreased significantly （P〉0.05）,and the experimental group had higher degree of decline.Conclusion Ciclesonide combined montelukast may reduce IL -6, TNF-α and sputum LTs levels in the treatment of serum.
出处
《黑龙江医学》
2014年第7期779-780,共2页
Heilongjiang Medical Journal
